Edition:
India

Roche Holding: FDA Approval For Xofluza


Friday, 18 Oct 2019 

Oct 18 (Reuters) - Roche Holding Ag ::ROCHE ANNOUNCES FDA APPROVAL OF XOFLUZA (BALOXAVIR MARBOXIL) FOR PEOPLE AT HIGH RISK OF DEVELOPING INFLUENZA-RELATED COMPLICATIONS.XOFLUZA IS THE FIRST AND ONLY ANTIVIRAL MEDICINE INDICATED SPECIFICALLY FOR PATIENTS AT HIGH RISK OF DEVELOPING SERIOUS COMPLICATIONS FROM INFLUENZA.